Reply to: 'IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma'
Nat Med
.
2019 Dec;25(12):1836-1838.
doi: 10.1038/s41591-019-0646-5.
Epub 2019 Dec 5.
Authors
Noam Auslander
1
,
Joo Sang Lee
2
3
,
Eytan Ruppin
4
Affiliations
1
National Center for Biotechnology Information, National Library of Medicine, US National Institutes of Health, Bethesda, MD, USA.
2
Cancer Data Science Lab (CDSL), National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA.
3
Samsung Medical Center, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
4
Cancer Data Science Lab (CDSL), National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA. eyruppin@gmail.com.
PMID:
31806908
DOI:
10.1038/s41591-019-0646-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Ipilimumab
Melanoma*
Substances
Ipilimumab